Cyclacel Pharmaceuticals Inc (CYCC NASDAQ) stock market data APIs
$0.3332
0(0%)
as of June 30, 2025
Try our APIs with
free plan!
Cyclacel Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
Prev. Close
0.3332
Open
0.3332
High
0.3332
Low
0.3171
52 wk Range
0.25-38.5309
Market Cap
7 864 K
P/E Ratio
0.1149
Shares Outstanding
23 760 K
Revenue
14 000
EPS
-0.3443
Dividends (Yield)
0
Beta
0.247
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cyclacel Pharmaceuticals Inc data using free add-ons & libraries
Get Cyclacel Pharmaceuticals Inc Fundamental Data
Cyclacel Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 14 000
- EBITDA: -12 679 500
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cyclacel Pharmaceuticals Inc News
New
Cyclacel raises $3M in private placement
* Cyclacel Pharmaceuticals (NASDAQ:CYCC [https://seekingalpha.com/symbol/CYCC]) has raised $3M through a private placement of convertible Series F Preferred Stock, issuing warrants to purchase up to...
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
BERKELEY HEIGHTS, N.J., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
BERKELEY HEIGHTS, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
- Cyclacel Expects to Release Updated Phase 1/2 Clinical and Biomarker Data with Oral Fadraciclib and Provide Safety, Efficacy and Putative Mechanism Update for Oral Plogosertib - - Management to Hos...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
